Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | PDE1A | P54750 | 2/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696684 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2PDE1BLTA4HHRH2PDE1A | |
| SCHEMBL3509984 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2PDE1BLTA4HHRH2PDE1A | |
| SCHEMBL12214 | 0.83 | LTA4H (0.57) | PDE1BLTA4HHRH3ALDH1A1 | |
| SCHEMBL14960477 | 0.83 | LTA4H (0.57) | PDE1BLTA4HHRH3ALDH1A1 | |
| SCHEMBL30460552 | 0.82 | LTA4H (0.56) | PDE1BLTA4HHRH3ALDH1A1 | |
| SCHEMBL30508309 | 0.82 | LTA4H (0.56) | SMN1; SMN2PDE1BLTA4HHRH3ALDH1A1 | |
| SCHEMBL30308375 | 0.82 | LTA4H (0.56) | PDE1BLTA4HHRH3ALDH1A1 | |
| SCHEMBL8805178 | 0.82 | LTA4H (0.56) | PDE1BLTA4HHRH3ALDH1A1 | |
| SCHEMBL1177023 | 0.82 | SIGMAR1 (0.57) | SMN1; SMN2ALDH1A1GAAMAPTHPGD | |
| SCHEMBL1177324 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2PDE1BALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459307-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC (US) | 2021-07-01 | — | — | US | disclosed |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-9868708-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868708-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868708-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160229815-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160229815-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2016-08-11 | — | — | US | disclosed |
| CN-102656163-A | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX | 2012-09-05 | — | — | CN | disclosed |
| EP-2473504-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | Bioenergenix (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2011028947-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028947-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | SMN1; SMN2 3582/4885PDE1B 795/4885LTA4H 2311/4885 |
| US-11459307-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | SMN1; SMN2 3582/4885PDE1B 795/4885LTA4H 2311/4885 |
| US-20160229815-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | SMN1; SMN2 3582/4885PDE1B 795/4885LTA4H 2311/4885 |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | SMN1; SMN2 3582/4885PDE1B 795/4885LTA4H 2311/4885 |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | SMN1; SMN2 3716/4885PDE1B 1396/4885LTA4H 4190/4885 |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | SMN1; SMN2 3582/4885PDE1B 795/4885LTA4H 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.